ANIP PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d ⚠ clustered

ANIP ▲ +7.11% at T+20d

LONG call ✓ call won +7.11% · α vs SPY -1.43% · entry $79.01 → $84.63

Next anchor: T+60d in 6w

Last close $82.72 (close May 22) · +4.70% from $79.01 entry

Entry anchored
Apr 7, 03:59 PM ET
via Databento tick

T+1d

+1.43%

call +1.43% · α +0.86%

$80.14

settled 6w ago

T+5d

-3.20%

call -3.20% · α -6.72%

$76.48

settled 6w ago

T+20d

+7.11%

call +7.11% · α -1.43%

$84.63

settled 18d ago

T+60d

—

call — · α —

—

in 6w

Price Chart

Loading chart...

Executive Summary

ANI Pharmaceuticals announced FDA approval and immediate launch of Isosorbide Mononitrate Tablet USP, 10 mg and 20 mg, the generic version of Monoket®, reinforcing its generics pipeline and R&D execution. The product targets a limited-competition market, supporting near-term revenue diversification.

Actionable Insight

Traders should monitor near-term sales uptake and gross margin trends, as limited-competition generics typically offer strong profitability. This approval adds to ANI’s track record of successful ANDA approvals and may support valuation re-rating if commercial execution continues.

Key Facts

FDA approved ANI's Abbreviated New Drug Application (ANDA) for Isosorbide Mononitrate Tablet USP, 10 mg and 20 mg.
Product launched immediately as a generic version of Monoket®.
Indication is for cardiovascular conditions, with limited competition expected.
Strengthens ANI’s Generics business and R&D track record.

Financial Impact

Moderate revenue contribution expected; exact sales figures not disclosed but positioned as part of steady product launch cadence.

revenueproduct pipelinemarket share

Risk Factors

Uncertainty around market adoption and competition despite 'limited-competition' claim.
Supply chain or manufacturing delays could hinder revenue realization.

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3269952

12 reports for ANIP

T+1T+5T+20T+60

25% Hit rate 1 of 4 directional calls best @ T+5▲ +3.53%Mar 9, 2026

Filters

Reports for ANIP — sortable, filterable
	Type				Now
May 21, 2026 2d ago	8-K NEUTRAL ★ 3/10	—	awaiting T+1	—	—
May 13, 2026 10d ago	8-K BULLISH ★ 7/10	$80.88 $79.58	▼ −1.61%	▼ −2.38%	$82.72 (+2.27%)
May 11, 2026 13d ago	Insider Cluster NEUTRAL ★ 4/10	$78.71 $79.50	▲ +1.00%	▲ +1.14%	$82.72 (+5.09%)
May 8, 2026 15d ago	8-K BULLISH ★ 8/10	$81.86 $78.71	▼ −3.85%	▼ −4.08%	$82.72 (+1.05%)
May 8, 2026 15d ago	Press Release BULLISH ★ 8/10	$81.86 $78.71	▼ −3.85%	▼ −4.08%	$82.72 (+1.05%)
Apr 24, 2026 29d ago	Press Release NEUTRAL ★ 3/10	$78.64 $79.60	▲ +1.22%	▲ +1.06%	$82.72 (+5.19%)
Apr 8, 2026 6w ago	Press Release BULLISH ★ 7/10	$79.01 $80.14	▲ +1.43%	▲ +0.86%	$82.72 (+4.70%)
Apr 7, 2026 6w ago	8-K NEUTRAL ★ 4/10	$79.01 $80.14	▲ +1.43%	▲ +0.86%	$82.72 (+4.70%)
Apr 7, 2026 6w ago	Press Release NEUTRAL ★ 4/10	$79.47 $79.01	▼ −0.58%	▼ −3.12%	$82.72 (+4.09%)
Mar 9, 2026 10w ago	Insider Cluster BEARISH ★ 6/10	$74.81 $75.96	▼ −1.54%	▼ −1.72%	$82.72 (−10.57%)

US Market Status

Market Closed — Opens Tue (35h 14m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access